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ABSTRACT  
Objective. Fatigue is consistently ranked as one of the most problematic symptoms in systemic 
sclerosis (SSc), but the impact of fatigue on daily life is not well-characterized. The purpose of this 
study was to examine fatigue’s contribution to deficits in social participation, functioning, and quality 
of life. 
Methods. Baseline data from a sample undertaking a clinical trial were utilized (N = 267). Fatigue, 
pain interference, depressive symptoms, physical function, and social participation were assessed by 
PROMIS measures. Hierarchical linear regressions were performed to determine fatigue’s unique 
contribution to social participation, physical function, and quality of life, above and beyond the 
effects of demographic and clinical variables, pain interference, and depressive symptoms. 
Results. The sample was predominantly female (91%), with average age 53.7 years, average disease 
duration of 9 years, and mean fatigue T-score of 58.7. Of all outcomes, fatigue was most strongly 
associated with deficits in social participation, explaining 48% of the variance beyond demographic 
and clinical factors, which is similar to the amount of variance contributed by pain interference and 
depressive symptoms combined (49%). Fatigue also accounted for significant amounts of variance in 
physical function and quality of life (R2 = .27 and .33 respectively) above and beyond the effects of 
demographic and clinical factors.
Conclusion. Fatigue is an important clinical problem in SSc and is strongly associated with decreased 
participation in social roles and activities. Rehabilitation interventions that focus on fatigue 
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SIGNIFICANCE AND INNOVATIONS
 Fatigue is associated with physical function, quality of life, and social participation. People 
with SSc and higher levels of fatigue had reduced ability to participate in social roles and 
activities. 
 Fatigue explains the same amount of variance in social participation as pain and depressive 
symptoms combined. After pain and depressive symptoms are in the model, fatigue explains 
an additional 9% of variance in social participation.
 Fatigue was a significant predictor of physical function and quality of life, though pain 
interference and depressive symptoms accounted for more variability, suggesting that different 
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Systemic sclerosis (SSc) is a rare autoimmune disease associated with vascular damage and tissue 
fibrosis that affects the skin and internal organs (1-3). In the US, it affects between 13.5 – 39.9 per 
100,000 people (4).  In addition to the classic skin hardening that restricts movement, a major 
complaint of people with SSc is the substantial symptom burden. Symptoms such as fatigue, pain, and 
depressive symptoms are common, and because SSc is diagnosed in early to middle age and has no 
cure, individuals with SSc face many years of managing the manifestations of a complex and 
progressive condition (5).
Symptoms in SSc significantly disrupt daily activities and diminish quality of life (6-9). 
Of the symptoms experienced, fatigue has been consistently ranked as one of the most problematic (6, 
7, 10-12). Fatigue in SSc is significantly greater than what is experienced by the general population, 
similar to other rheumatological conditions and those who are actively in cancer treatment (8,9,12). 
Fatigue affects many facets of life, diminishing the ability to perform usual tasks (7, 13), engage in 
meaningful activities (7, 14), perform work duties (15, 16) and fulfill family responsibilities (14, 17, 
18). The debilitating nature of fatigue has prompted a call for research to better understand fatigue 
and its correlates (6, 7, 9, 14) in order to better address this symptom to reduce disability and improve 
quality of life.       
To better understand the contribution of fatigue to functioning and quality of life in SSc, we examined 
baseline data from a sample of participants who undertook a clinical trial investigating the 
effectiveness of an internet-based self-management program (19). The purpose of this study was to 
examine fatigue’s contribution to deficits in social participation, functioning, and quality of life in 
people with SSc. We hypothesized that fatigue would be the strongest unique contributor to each of 
these outcomes in multivariable models that included other symptoms (pain interference and 
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Adults with SSc were recruited to participate in a randomized controlled trial designed to evaluate the 
efficacy of an internet-based chronic disease self-management program (19). People were recruited 
from two universities (in the Midwest and South Eastern United States) as well as from websites and 
social media from national SSc foundations. To be included in the trial, people needed to be US 
residents, report a diagnosis of SSc, be 18 years or older, have basic computer literacy and access to a 
computer with internet and email capabilities, be able to communicate in English, and be willing to 
complete the study procedures. All participants provided informed consent. After informed consent 
was obtained, participants were sent a Qualtrics survey to complete baseline assessments examined in 
this secondary data analysis. The study was approved by institutional human subjects review boards at 
the University of New Mexico, University of Michigan, and Medical University of South Carolina.
Measures
Fatigue. Fatigue was measured using the 4 items from the fatigue subscale of the Patient Reported 
Outcomes Measurement Information System (PROMIS) 29 version 2.0 (v.2). The PROMIS 29 v.2 
contains several scales used in this analysis which have been validated in a large international sample 
of people with SSc (20). Items are referenced for the past 7 days and rated on a scale from 1 (not at 
all) to 5 (very much): 1) I feel fatigued; 2) I have trouble starting things because I am tired; 3) How 
run-down did you feel on average? and 4) How fatigued were you on average? Ratings were 
converted to a T score metric which standardized the ratings to the US population in which the mean 
is 50 and standard deviation is 10. A higher score indicates worse fatigue. 
Outcomes
Social Participation. The Ability to Participate in Social Roles and Activities scale was part of the 
PROMIS 29 and consists of 4 items. On a scale of 5 (Never) to 1 (Always), participants were asked to 
rate the following: 1) I have trouble doing all of my regular leisure activities with others
2) I have trouble doing all of the family activities that I want to do; 3) I have trouble doing all of my 
usual work (include work at home) and 4) I have trouble doing all of the activities with friends that I 
want to do. Scores were converted to T scores for analysis. A higher score indicates better ability. 
Physical Function. The PROMIS 29 v.2 has a physical function scale with 4 items. On a scale of 5 
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able to do chores such as vacuuming or yard work?  2) Are you able to go up and down stairs at a 
normal pace?  3) Are you able to go for a walk of at least 15 minutes? and 4) Are you able to run 
errands and shop? A higher score indicates better physical function.  
Quality of Life. The EuroQol 5-domain instrument (EQ-5D-5L) is a generic health-related quality of 
life assessment commonly used in samples with various chronic conditions (21, 22). It has domains of 
mobility, self-care, activity, pain, and anxiety. Participants are asked to rate their health state on a 
scale of no problems, slight problems, moderate problems, severe problems and extreme problems. 
Responses are then transformed to a metric of health utility using an algorithm in which scores range 
from 0.0 (death) to 1.0 (full/optimal health).
Demographic and Clinical Characteristics
Demographic information included age, race, ethnicity, sex, education level, marital status, and 
employment status. Clinical characteristics included scleroderma type (limited/CREST/sine, diffuse, 
or overlap), and disease duration (measured as the year diagnosed).  Self-rated health was ascertained 
through one question in which participants rated their overall health as excellent, very good, good, 
fair, or poor. 
Other Symptoms
Pain interference and Depressive symptoms. Both of these symptoms were assessed from the 
PROMIS scales from the PROMIS 29 v.2. Pain interference was assessed by 4 items. In the past 7 
days, participants rated pain interference on a scale of 1 (not at all) to 5 (very much) in the following 
questions: 1) How much did pain interfere with your day to day activities? 2) How much did pain 
interfere with work around the home? 3) How much did pain interfere with your ability to participate 
in social activities? and 4) How much did pain interfere with your household chores? Depressive 
symptoms were also assessed in the past 7 days. On a scale of 1 (never) to 5 (always), participants 
rated the following: 1) I felt worthless; 2) I felt helpless; 3) I felt depressed; and 4) I felt hopeless. 
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Descriptive statistics were used to characterize the sample. We used frequency and proportion for 
categorical variables, means and standard deviations for normally distributed continuous data and 
median and interquartile ranges for non-normally distributed continuous data. The association 
between fatigue (T score from the PROMIS measure) and three outcome variables was investigated in 
three separate hierarchical multivariable linear regression analyses with outcome variables: social 
participation, physical function, and quality of life. For each outcome, 3 models were constructed to 
examine the relative contributions of fatigue and other symptoms (pain interference and depressive 
symptoms) above and beyond demographic and clinical variables. This method allowed us to examine 
the unique contribution of fatigue and the set of other symptoms respectively to the model variance 
without the influence of each other. It also allowed for comparison across models given the difference 
in order of entry. In Model 1, demographic and clinical variables (age, gender, race, scleroderma 
subtype, and years since scleroderma diagnosis) were entered in Block 1 and fatigue was entered in 
Block 2. In Model 2, demographic and clinical variables were entered in Block 1, fatigue in Block 2, 
and pain interference and depressive symptoms in Block 3. Model 2 was performed to examine how 
much the symptom of fatigue explained the variance in each outcome above and beyond clinical 
factors, and how much unique variance is then explained by pain interference and depressive 
symptoms. In Model 3 the order of entry of the pain interference and depressive symptoms block and 
the fatigue block were reversed. Model 3 was performed to examine how much unique variance 
fatigue adds to the model above and beyond demographic and clinical variables and symptoms of pain 
interference and depressive symptoms. R2 values indicated the amount of variance in the outcomes 
attributable to the variable blocks entered into the models. To depict the unadjusted relationship 
between fatigue and social participation, a scatter plot with overlaid best-fitting lines was constructed, 
estimated using ordinary least squares piecewise regression. We pre-specified a cut-point of 1SD 
below the sample fatigue T-score mean. 
 
RESULTS
The characteristics of the sample have been reported in detail elsewhere (19). In brief, the sample was 
predominantly female (91%), the mean age was 53.7 years (SD 11.7), and consisted of 17% 
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or professional qualifications with a mean of 16 years of education; 64% were married, and 42% 
reported working part or fulltime. For the scleroderma subtype reported by participants, 45% had 
limited cutaneous systemic sclerosis or sine scleroderma; 43% had diffuse cutaneous systemic 
sclerosis; 12% had scleroderma overlapping with another rheumatic disease, and 0.4% (n = 1) did not 
know the subtype. Time since diagnosis was a median of 9 years with an interquartile range of 5 – 16. 
Table 1 shows the values for reported functioning, health, and symptom measures. 43.9% of the 
sample rated their overall health to be fair or poor. Fatigue was the worst rated symptom (Mean T = 
58.7 or 0.87 SD above the US Population) followed by pain interference (Mean T = 58.0). Mean 
anxiety, sleep disturbance, and depressive symptoms were all within .5 standard deviations of the 
normative sample mean (T = 50). Using one way analyses of variance or chi-square tests to examine 
differences across SSc subtype, only fatigue, sleep disturbance, and self-rated health were 
significantly different (p < 0.05). Participants with overlap SSc had the highest levels of fatigue and 
sleep disturbance, and the highest proportion of people who rated their health as fair or poor (51.6%). 
Participants with diffuse SSc also had a high proportion of people who rated their health as fair or 
poor (50.5%), but their mean fatigue and sleep disturbance levels were similar to those with limited or 
sine SSc.   
Fatigue and Social Participation 
Table 2 shows results from hierarchical regression models where fatigue and other variables were 
examined as predictors of social participation. In Model 1, 50% of the variance in social participation 
was explained by demographic and clinical factors, which contributed a negligible amount (2%) of 
variance and by fatigue, which accounted for nearly half (48%) of the variance. Of the demographic 
and clinical factors, age and the diffuse SSc subtype demonstrated significant independent negative 
associations with social participation. When pain interference and depressive symptoms were added 
in a block after fatigue (Model 2), a further increase of 11% of variance in the outcome was explained 
by these symptoms. In the Model 3, fatigue accounted for a significant amount of variance (9%) 
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variance). Regardless of order of entry, the models accounted for approximately 60% of the variance 
in social participation.
Figure 1 shows the unadjusted association between fatigue and social participation, with the best-fit 
line segmented at 1SD below the sample mean (fatigue mean T score 48). In this graph, the negative 
association between fatigue and social participation is only seen when people have fatigue that is 
approximately at the mean or greater (T-score of 48 or higher). Fatigue was not associated with social 
participation for people with low fatigue.  
Fatigue and Physical Function 
Table 3 shows the results from the hierarchical regression models where physical function was the 
outcome. In Model 1, 30% of the variance in physical function was explained by demographic and 
clinical factors (3% combined) and fatigue (27% of the variance). Age and diffuse SSc were 
significantly negatively associated with physical function and depressive symptoms. In Model 2, 
fatigue accounted for a significant and substantial amount of variance in physical function (27%); 
pain and depressive symptoms added a significant amount of variance above and beyond the effect of 
fatigue on physical function. In Model 3, pain interference and depressive symptoms accounted for a 
substantial and significant amount of variance in physical function (37%); fatigue added a statistically 
significant though small amount of variance in physical functioning when added in the third step. The 
models accounted for 43% of the variance in self-reported physical function.
Fatigue and Quality of Life
Table 4 shows the results from the hierarchical regression models where quality of life was the 
outcome. In Model 1, 35% of the variance in quality of life was explained by demographic and 
clinical factors and fatigue; as in prior models, demographic and clinical variables accounted for very 
small amounts of the variance in quality of life (2%), whereas fatigue accounted for 33% of the 
variance. Of the demographic factors, diffuse SSc was significantly associated with lower quality of 
life. In Model 2, pain interference and depressive symptoms contributed an additional 21% variance 
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contributed an additional 1% variance in quality of life, above the variance explained by pain 
interference and depressive symptoms, which accounted for 53% of the variance in quality of life. 
These models explained 56% of the variance in quality of life and depressive symptoms.    
DISCUSSION
Fatigue is a symptom often described in the literature as debilitating by people with SSc (6, 10, 11), 
but it is not yet clear what aspects of functioning and quality of life are most affected by fatigue and 
other symptoms. In this study, our objective was to examine fatigue’s contribution to deficits in social 
participation, functioning, and quality of life. To accomplish this, we examined the relative 
contributions of fatigue above and beyond demographics and clinical factors and other symptoms 
(pain interference and depression).
We have three main findings from this study. First, of all outcomes assessed, fatigue was most 
strongly associated with decreased ability to participate in social roles and activities. Fatigue alone 
accounted for nearly the same amount of variance in social participation (R2 = .48 in Table 2 Model 
2) as pain interference and depressive symptoms combined (R2 = .49 in Table 2 Model 3).  
Furthermore, the substantial amount of unique variance that fatigue explained over and above 
symptoms of pain interference and depressive symptoms suggest that fatigue is particularly influential 
with regard to reduced social participation. These findings are in contrast to those of Sandusky et al. 
who reported that fatigue was not a significant correlate for social participation after controlling for 
depressive symptoms (7) and Poole et al. (24) using a single VAS measure for fatigue, who reported 
no difference in social participation with higher levels of fatigue. However, there are several key 
differences in the measurement of social participation between the current study and those studies. 
Sandusky et al. measured social participation via social networks and relationships as opposed to 
participation in particular activities, and Poole et al. measured social participation by ascertaining 
frequency of performance of activities, such as gardening, household maintenance, and shopping, and 
counted higher frequency as better participation. In the current study, social participation was 
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usual social activities and factors in the whether participation is above or below what the individual 
wants to do. In addition, the PROMIS social participation has been validated and has stronger 
psychometric properties compared to the instruments used in the prior studies. Lastly, differences in 
this study’s sample and those studies may also affect the comparisons. For instance, in the Sandusky 
et al study, a higher proportion of people reported having a high school education or less (32%) in 
relation to this sample (20%). 
One reason why fatigue may have a strong negative association to social participation is because work 
limitations are included in the social participation measure. In SSc, fatigue is a strong correlate of 
work disability (25,26), and baseline fatigue severity was a main predictor of work disability in a 
longitudinal study (27). This study’s findings showing a strong negative association between fatigue 
and social participation is similar to that of studies in another chronic condition, multiple sclerosis 
(28,29). In those studies, pain and depressive symptoms are also important factors in decreased 
physical function and quality of life. 
Our findings have implications for both assessment and intervention development. While clinical 
assessment often includes measures of physical function, it appears important to include measures of 
social participation when assessing patients with SSc, especially if they report high fatigue. In 
addition, the assessment used to measure fatigue is an important consideration also as some 
assessments such as the Multidimensional Fatigue Inventory and Multidimensional Assessment of 
Fatigue Scale include items asking about the impact of fatigue on participation. Assessment of social 
participation may reveal areas for intervention that would be appropriate for rehabilitation 
professionals to address, such as workplace adaptation, and also supports the idea that fatigue 
management is necessary in this population, similar to others recommendations (6, 7, 9, 12, 14). 
Second, although fatigue accounted for about one third of the variance in physical function and 
quality of life outcomes when entered in the models prior to the addition of pain interference and 
depressive symptoms, fatigue did not significantly contribute to the variance in physical function and 
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findings suggest that interventions to impact physical function and quality of life need to be 
multifaceted and include strategies to reduce pain and depressive symptoms in addition to fatigue 
management. Indeed, other studies have confirmed this relationship between fatigue, pain, depressive 
symptoms and function (7, 12, 30).
Third, this finding extends the understanding of how demographics and clinical factors relate to 
symptoms, functioning and quality of life in SSc. Neither age nor disease subtype was associated with 
the outcomes measured. Interestingly, people with SSc all have relatively high symptom severity 
compared to normative samples and people with the two main subtypes of SSc (diffuse and limited) 
have somewhat similar fatigue levels (T = 57 and 58). This is similar to a previous study that showed 
no significant differences in fatigue by subtype (7). Although fatigue severity was similar in these 
groups, people with diffuse SSc have greater deficits in their ability to participate in social roles and 
activities suggesting that fatigue management is particularly important in this group.  Moreover, lung, 
gastrointestinal and muscle involvement, more common with diffuse SSc, have been reported to be 
predictors of fatigue (12). 
Limitations
This study utilized cross-sectional data so causality between fatigue and outcomes cannot be assumed. 
Further, participants were a national sample who self-reported all measures via survey so clinical 
variables could not be corroborated by medical records. In addition, other measures of health status 
such as number and types of comorbidities were not collected and this information could have further 
explained variance in the functioning and quality of life outcomes. Future studies should examine 
longitudinal associations between fatigue and social participation. 
Conclusion
This study showed that fatigue related strongly to deficits in the ability to participate in social roles 
and activities. Intervention development for fatigue management may be particularly needed to 
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FIGURE LEGEND.
Figure 1. Unadjusted Relationship between Fatigue and Social Participation  
Note. Social participation is measured by the PROMIS Ability to Participate in Social Roles and 
Activities. Both axes depict T scores. The cut-point used (depicted by the dotted line above) is 1 SD 
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Table 1. Sample Reported Symptoms, Functioning, and Quality of Life (N = 267) 







Fatigue* 58.7 (10.4) 57.5 (10.1) 58.4 (10.4) 63.7 (10.1) 
Pain interference 58.0 (9.3) 56.9 (9.7) 58.0 (8.8) 61.4 (8.9) 
Pain intensity (0–10 NRS) 4.2 (2.2) 3.9 (2.3) 4.2 (2.1) 4.9 (2.2) 
Depressive symptoms  51.3 (9.8) 51.3 (10.1) 51.3 (10.0) 51.6 (8.7) 
Anxiety 54.0 (10.0) 53.4 (9.9) 54.4 (10.1) 54.7 (10.5) 
Sleep disturbance * 53.7 (6.5) 53.9 (6.5) 52.5 (5.7) 57.0 (8.2) 
Social Participation 45.0 (8.2) 44.9 (8.0) 45.8 (8.5) 43.3 (7.2) 
Quality of Life EQ-5D-5L 0.78 (0.08) 0.78 (0.08) 0.79 (0.08) 0.77 (0.07) 
Self-rated health (n, %)* 
  Excellent 
  Very good 
  Good 
  Fair  

























Note. The PROMIS 29 v.2 was used which comprised scales of Fatigue, Pain Interference, Pain 
Intensity, Depressive symptoms, Anxiety, Sleep Disturbance, Ability to Participate in Social 
Roles (Social Participation), and Physical Function. Unless otherwise noted, statistics 
represented in the table show the mean (standard deviation) for each variable. * p < 0.05 
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Table 2. The Association of Fatigue with Ability to Participate in Social Roles  
 Model 1 Model 2 Model 3 
 Block B ∆R2 Block B ∆R2 Block B ∆R2 




1  .02 1  .02 1  .02 
   Age  -0.10*   -0.12*   -0.12*  
   Female  1.62   1.51   1.51  
   Minority  1.03   1.51   1.51  
   Diffuse SSc
†
  -1.49*   -1.65*   -1.65*  
   Overlap SSc
†
  0.10   -0.19   -0.19  
   Diagnosis year  -0.04   -0.03   -0.03  
Fatigue 2 -0.56* .48* 2 -0.32* .48* 3 -0.28* .09* 




    -0.16*   0.32*  
Total Model R2   .50   .61   .60 
Note. Fatigue, Ability to Participate in Social Roles and Activities, Pain Interference, and 
Depressive symptoms are scales taken from the PROMIS 29 v.2. Hierarchical regression models 
were constructed with variable(s) entered in blocks. Beta coefficients included in the table are 
from full models; ∆R2 is shown for Pain Interference and Depressive symptoms in combination 
as they were entered together in a block. N=266 in all models (1 participant had missing data for 
SSc type). 
†
 Reference group: Limited or sine scleroderma  *p < .05  
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 Model 1 Model 2 Model 3 
 Block B ∆R2 Block B ∆R2 Block B ∆R2 




1  .03 1  .03 1  .03 
   Age  -0.07*   -0.09*   -0.09*  
   Female  0.84   1.13   1.13  
   Minority  0.47   1.00   1.00  
   Diffuse SSc
†
  -1.84*   -2.05*   -2.05*  
   Overlap SSc
†
  -1.23   -1.15   -1.15  
   Diagnosis year  -0.07   -0.06   -0.06  
Fatigue 2 -0.36* .27* 2 -0.16* .27* 3 -0.16* .03* 




    -0.03   -0.03  
Total Model R2   .30   .43   .43 
Note. Fatigue, Physical Function, Pain Interference, and Depressive symptoms are scales taken 
from the PROMIS 29 v.2. Hierarchical regression models were constructed with variable(s) 
entered in blocks. Beta coefficients included in the table are from full models; ∆R2 is shown for 
Pain Interference and Depressive symptoms in combination as they were entered together in a 
block. N=266 in all models (1 participant had missing data for SSc type). 
†
 Reference group: 
Limited or sine scleroderma  *p < .05  
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Table 4. The Association of Fatigue with Quality of Life   
Note. Quality of Life was measured using the EuroQol 5D-5L instrument. Fatigue, Pain 
Interference, and Depressive symptoms are scales taken from the PROMIS 29 v.2. Hierarchical 
regression models were constructed with variable(s) entered in blocks. Beta coefficients included 
in the table are from full models; ∆R2 is shown for Pain Interference and Depressive symptoms 
in combination as they were entered together in a block. N=266 in all models (1 participant had 
missing data for SSc type). 
†
 Reference group: Limited or sine scleroderma  *p < .05  
 Block B ∆R2 Block B ∆R2 Block B ∆R2 




1  .02 1  .02 1  .02 
   Age  -0.0001   -0.0004   -0.0004  
   Female  0.02   0.02   0.02  
   Minority  -0.004   0.002   0.002  
   Diffuse SSc
†
  -0.01   -0.02*   -0.02*  
   Overlap SSc
†
  -0.004   -0.008   -0.008  
   Diagnosis year  -0.0004   -0.0003   -0.0003  
Fatigue 2 -0.005* .33* 2 -0.001* .33* 3 -0.001* .01* 




    -0.002*   -0.002*  
Total Model R2   .35   .56   .56 
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